Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Recent Articles in Deals & Financings

METiS Acquires Rights to Pan-RAF Inhibitor in $482 Million Agreement
Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing
Celregen Therapeutics In-Licenses iPS Therapy for Cornea Transplants in $100 Million Deal
Worg Pharma Completes $57 Million Series B for Novel Allergy and Autoimmune Therapies
Advanced MedTech Acquires WIKKON, a Shenzhen Urology Device Maker
ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022